Skip to content
Evigrade
MajorClass III antiarrhythmics (Vaughan Williams)×Antianginal – late sodium current inhibitor

Updated · Methodology

Mechanism

Ranolazine blocks the IKr potassium current and prolongs the heart-rate-corrected QT interval (QTc) in a concentration-dependent way (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Amiodarone is a class III antiarrhythmic that itself prolongs the QT interval, and the risk of torsade de pointes may rise when it is combined with other QT-prolonging drugs (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ranolazine is a substrate of CYP3A4 and of the transporter P-glycoprotein (P-gp), and their inhibitors raise its levels (EMA). Amiodarone and its metabolite inhibit CYP3A4 and P-gp (AEMPS), but the documents do not say how much amiodarone raises ranolazine levels. In turn, ranolazine weakly inhibits CYP3A4 (EMA), the main liver enzyme that metabolises amiodarone (AEMPS). The half-life of amiodarone is 20 to 100 days, so interactions may persist for several months after it is stopped (AEMPS).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Proarrhythmic effects are less common with amiodarone than with other antiarrhythmics and usually occur with factors that prolong the QT interval, such as drug interactions and electrolyte disorders. New or worsening arrhythmias have been reported, sometimes fatal, and a slow heart rate is common (amiodarone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Higher ranolazine levels make its dose-related reactions, such as dizziness and nausea, more likely (ranolazine SmPC, European Medicines Agency, EMA). Warning signs of a possible arrhythmia are feeling faint or lightheaded and an irregular or fast heartbeat (ranolazine label, US Food and Drug Administration, FDA).

Management

Avoid the combination. The US amiodarone label says to avoid using it with drugs that prolong the QT interval because of the risk of torsade de pointes (amiodarone label, US Food and Drug Administration, FDA). The ranolazine documents state that ranolazine prolongs the heart-rate-corrected QT interval (QTc) in a dose-related way (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA; ranolazine FDA label). The Spanish amiodarone SmPC recommends avoiding CYP3A4 inhibitors (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and the ranolazine SmPC describes ranolazine as a weak CYP3A4 inhibitor (EMA). The pair is not contraindicated: the European ranolazine SmPC contraindicates class Ia and class III antiarrhythmics but explicitly excludes amiodarone (EMA). The Spanish amiodarone SmPC contraindicates the named drugs that induce torsade de pointes. For other QT-prolonging drugs, it requires a careful assessment of benefits and risks for each patient and QT monitoring (AEMPS). If the combination is still used, give ranolazine with caution, as with other drugs that affect QTc. Because amiodarone inhibits P-glycoprotein (P-gp), adjust the ranolazine dose carefully and reduce it if needed (EMA; AEMPS; ranolazine FDA label). The US ranolazine label limits the dose to 500 mg twice daily with moderate CYP3A inhibitors such as diltiazem, verapamil, erythromycin and fluconazole. Only the US label has this rule. Amiodarone is not on its list, and the US amiodarone label does not state how strongly amiodarone inhibits CYP3A (ranolazine and amiodarone FDA labels). Before starting amiodarone, record an electrocardiogram (ECG), check potassium and correct a deficit (AEMPS). The US label also requires correcting low magnesium and calcium before starting (amiodarone FDA label). Because of the long amiodarone half-life, the interaction may persist for several months after amiodarone is stopped (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Amiodarone

Other interactions with Ranolazine